Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 trial.

a TL1A inhibitor for ulcerative colitis and Daiichi-Sankyo-partnered antibody drug conjugates (ADCs). Declining Sales of Gardasil in China Sales of Merck’s second-largest product, its human ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

A month has gone by since the last earnings report for Merck (MRK). Shares have added about 3.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

Healthcare & Pharmaceuticalscategory· September 18, 2024 Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial Daiichi Sankyo and Merck said on Tuesday that ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

Key HER2+ Gastric Cancer companies in the market include - Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi ...

(RTTNews) - Biopharmaceutical company Merck & Co., Inc. (MRK ... a charge of $1.69 per share related to a collaboration with Daiichi Sankyo. Excluding items, adjusted earnings for the quarter ...